title: Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
abstract: The efficacy of the addition of lithium to an established course of antidepressant treatment can be explained by a synergistic effect of the two drugs on central 5-HT neurotransmission. In the present study we investigated the effect of lithium addition on the 5-HT concentration in plasma and platelets and the concentration of 5-HIAA. Thirty-nine depressed inpatients who fulfilled the DSM-IV criteria for major depressive disorder and who did not respond to monotherapy with either imipramine or fluvoxamine participated in this study. Concentration of 5-HT in both plasma and platelets did not change significantly during lithium addition. The 5-HT ratio (plasma concentration/platelet concentration) shows a small non-significant increase after 3 weeks lithium addition. The mean concentration of 5-HIAA shows a significant increase during lithium addition; with no difference between the imipramine and the fluvoxamine sample. The increments in 5-HIAA concentration during lithium addition are indicative of an increased 5-HT turnover.
authors.affiliation: Department of Psychiatry, Erasmus Medical Centre, Rotterdam, The Netherlands. t.birkenhager@erasmusmc.nl
authors.forename: Tom K
authors.initials: TK
authors.lastname: Birkenhäger
authors.forename: Walter W
authors.initials: WW
authors.lastname: van den Broek
authors.forename: Durk
authors.initials: D
authors.lastname: Fekkes
authors.forename: Paul G
authors.initials: PG
authors.lastname: Mulder
authors.forename: Peter
authors.initials: P
authors.lastname: Moleman
authors.forename: Jan A
authors.initials: JA
authors.lastname: Bruijn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D018692:Antimanic Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003866:Depressive Disorder / Q000097:blood* / Q000188:drug therapy* / Q000523:psychology; D004351:Drug Resistance; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood*; D007099:Imipramine / Q000627:therapeutic use; D018020:Lithium Compounds / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012701:Serotonin / Q000097:blood*
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D018692:Antimanic Agents; D018020:Lithium Compounds; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D016666:Fluvoxamine; D007099:Imipramine